Loading…
CalciMedica, Inc. is projected to rise to $1.53 by 2027, a +64% move from its current price of $0.93. CALC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.8605 | $0.9319 | $1.01 | +0.21% |
| Jul 14 | $0.8342 | $0.9339 | $1.05 | +0.41% |
| Jul 15 | $0.815 | $0.9358 | $1.07 | +0.62% |
| Jul 16 | $0.7995 | $0.9377 | $1.10 | +0.83% |
| Jul 17 | $0.7862 | $0.9397 | $1.12 | +1.04% |
| Jul 18 | $0.7745 | $0.9416 | $1.14 | +1.25% |
| Jul 19 | $0.7641 | $0.9436 | $1.17 | +1.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7641 | $0.9436 | $1.17 | +1.46% |
| Week 2 | $0.7103 | $0.9573 | $1.29 | +2.94% |
| Week 3 | $0.6739 | $0.9712 | $1.40 | +4.44% |
| Week 4 | $0.6461 | $0.9854 | $1.50 | +5.96% |
| Week 5 | $0.6237 | $0.9998 | $1.60 | +7.50% |
| Week 6 | $0.6049 | $1.01 | $1.70 | +9.07% |
| Week 7 | $0.5888 | $1.03 | $1.80 | +10.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitor for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease.
CalciMedica is based in La Jolla, California, and operates in the Healthcare sector. The description reflects its focus on inflammatory and immunologic conditions and related cellular damage, with Auxora as the lead candidate and additional CRAC channel inhibitor programs in development.
CalciMedica, Inc. (CALC) is a healthcare stock currently trading around $0.90 per share. Its market capitalization is $14.22M, and it is ranked 5016 by market capitalization. The stock shows a mixed near-term technical posture with a bullish sentiment in the longer-run outlook.
The current price and modest market cap position suggest the stock is relatively small-cap and speculative in nature, with a path toward higher valuations suggested by the multi-year forecast table. The 30-day technical picture shows a bullish tilt in sentiment and key support/resistance levels to watch. The annualized volatility is high at 200%, underscoring substantial risk alongside any upside.
Overall, the price outlook across the forecast horizon indicates potential upside, with longer-term targets rising significantly from 2027 onward and a bullish sentiment prevailing through 2050, albeit with notable uncertainty inherent in small-cap biotech equities.
A major floor 57.1% below — a decisive break under it would weaken the trend.
The nearest floor, 35.8% below — buyers have tended to step in here.
The nearest ceiling, 14.0% above — a clean break opens room to run.
A major ceiling 42.5% above — clearing it would confirm fresh momentum.
Key CALC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CALC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9448 | Sell | $0.9389 | Sell |
| MA 10 | $0.9562 | Sell | $0.925 | Buy |
| MA 20 | $0.8725 | Buy | $0.8905 | Buy |
| MA 50 | $0.7809 | Buy | $0.8589 | Buy |
| MA 100 | $0.7034 | Buy | $1.13 | Sell |
| MA 200 | $2.21 | Sell | $1.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.22 | Neutral |
| Stoch RSI (14) | 67.21 | Neutral |
| CCI (20) | 41.97 | Neutral |
| Williams %R (14) | -24.83 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 15.82 | Buy |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 75.17 | Neutral |
| TRIX (15) | 0.77 | Buy |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 42.38 | Neutral |
| Momentum (10) | 0.30 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 0.92 | Buy |
| ADX (14) | 15.59 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bullish, with RSI14 at 50 and a leadership bias supported by the near-term price action. The stock’s 50-day simple moving average sits at $0.7666, while the 200-day moving average sits at $2.24, signaling that near-term momentum could shift if price tests resistance.
Key support is at $0.597 and resistance at $1.06, framing a tight range around current levels. Over the last 30 days, the price ranged from a low of $0.5175 to a high of $1.57, highlighting a broad swing despite the bullish tone. Given the volatility, traders should watch for breakouts above resistance or drops below support as signals for potential trend changes.
The asset exhibits high annualized volatility at 200%, indicating substantial risk and rapid price movements relative to broader markets.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.507 | $0.93 | $1.62 | 0% | Neutral | |
| $1.11 | $1.53 | $2.27 | +64% | Bullish | |
| $1.20 | $1.76 | $2.80 | +89% | Bullish | |
| $1.40 | $2.16 | $3.60 | +132% | Bullish | |
| $1.15 | $1.85 | $3.22 | +99% | Bullish | |
| $1.49 | $2.51 | $4.51 | +170% | Bullish | |
| $2.46 | $4.34 | $8.05 | +367% | Bullish | |
| $2.50 | $4.60 | $8.76 | +394% | Bullish | |
| $2.69 | $5.15 | $10.05 | +453% | Bullish | |
| $2.75 | $5.46 | $10.91 | +487% | Bullish | |
| $5.18 | $11.52 | $25.28 | +11.4x | Bullish | |
| $11.95 | $26.55 | $61.07 | +27.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.507 | $0.93 | $1.20 | +0.00% |
| August 2026 | $0.9055 | $1.10 | $1.39 | +17.99% |
| September 2026 | $0.9137 | $1.12 | $1.45 | +2.33% |
| October 2026 | $0.8756 | $1.09 | $1.43 | -2.99% |
| November 2026 | $0.9049 | $1.14 | $1.51 | +4.41% |
| December 2026 | $0.9478 | $1.20 | $1.62 | +5.76% |
Click any year to see its month-by-month CALC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CALC could reach as high as $1.62, with a base case around $0.93 and support toward $0.507 — roughly 0% from $0.93. Price action looks broadly range-bound.
Expect CALC to range from $1.11 to $2.27 through 2027. The $1.53 average target implies a +64% move from current prices. That is up +64% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The CALC price prediction for 2028 points to an average of $1.76 (low $1.20, high $2.80) — a potential gain of +89% on today's $0.93. Momentum favours further upside here.
In 2029, CALC is projected to trade between $1.40 and $3.60, averaging $2.16 — a potential gain of +132% from today's $0.93. That is up +23% on the projected 2028 average. Buyers look set to stay in control over this stretch.
CalciMedica, Inc.'s 2030 outlook centres on $1.85, within a $1.15 to $3.22 range. That is -14% versus the projected 2029 average. That marks a +99% change versus current levels. Momentum favours further upside here.
By 2031, CALC could reach as high as $4.51, with a base case around $2.51 and support toward $1.49 — roughly +170% from $0.93. Buyers look set to stay in control over this stretch.
Expect CALC to range from $2.46 to $8.05 through 2032. The $4.34 average target implies a +367% move from current prices. That is up +73% on the projected 2031 average. Momentum favours further upside here.
The CALC price prediction for 2033 points to an average of $4.60 (low $2.50, high $8.76) — a potential gain of +394% on today's $0.93. Buyers look set to stay in control over this stretch.
In 2034, CALC is projected to trade between $2.69 and $10.05, averaging $5.15 — a potential gain of +453% from today's $0.93. That is up +12% on the projected 2033 average. Momentum favours further upside here.
CalciMedica, Inc.'s 2035 outlook centres on $5.46, within a $2.75 to $10.91 range. That is up +6% on the projected 2034 average. That marks a +487% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CALC could reach as high as $25.28, with a base case around $11.52 and support toward $5.18 — roughly +11.4x from $0.93. Momentum favours further upside here.
Expect CALC to range from $11.95 to $61.07 through 2050. The $26.55 average target implies a +27.6x move from current prices. That is up +131% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CALC today (≈ 1,075.268817 CALC) could be worth
$28,552.05
+$27,552.05 (+2755%) by 2050 · US Dollar
Based on the average projected CALC price of $26.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CALCwould be worth at today's price.
$1,000 invested in CALC on Jul 10, 2025 (≈ 617.283949 CALC) would be worth
$574.07
-$425.93 (-42.6%) today · 0.57× · US Dollar
Based on a CALC entry price of $1.62 vs. today's $0.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.965 | $963.73 | -3.6% |
| 1 month ago | $0.932 | $997.85 | -0.2% |
| 3 months ago | $0.618 | $1,504.85 | +50.5% |
| 6 months ago | $5.4 | $172.22 | -82.8% |
| 1 year ago | $1.62 | $574.07 | -42.6% |
| All time (3.1y) ago | $5.84 | $159.25 | -84.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CALC forecast.
Our base-case forecast reaches $1.90 around 2029.
Implied market cap at $1.90: $30.02M
The multi-year forecast shows a path of growth with rising average prices and meaningful upside potential across the horizon. In 2026, the average is projected at $0.90 with a min of $0.507 and a max of $1.56 and anROI of 0, with neutral sentiment. The trajectory improves steadily thereafter, with 2027 at an average of $1.45, a min of $1.05, a max of $2.16, an ROI of 60.6%, and bullish sentiment.
In 2028, the average is $1.64, the min $1.12, the max $2.60, ROI 82.1%, and bullish sentiment; 2029 shows $1.95 average, $1.26 min, $3.25 max, ROI 116.5%, bullish. The 2030 forecast softens to an average of $1.63 with a min of $1.01 and a max of $2.83, ROI 81%, bullish. The forecast continues to show rising averages and substantial upside, with 2031 at $2.14 average, 2032 at $3.60 average, 2033 at $3.80 average, 2034 at $4.24 average, and 2035 at $4.43 average, all with bullish sentiment and progressively higher max targets.
Longer-horizon projections remain strongly bullish, with 2040 at an average of $8.89, a min of $4.00, a max of $19.52, ROI 887.7%, and bullish sentiment, and 2050 at an average of $18.90, a min of $8.50, a max of $43.47, ROI 1999.8%, bullish sentiment. These figures imply substantial potential upside over the extended horizon, though they also reflect the high uncertainty and risk inherent to small-cap biotechnology equities.
Tap a question to reveal the answer.
Avg $1.63; Min $1.01; Max $2.83; ROI 81; Sentiment BULLISH.
Yes. The forecast shows a max of $6.68 in 2032 and $7.23 in 2033, with higher targets in subsequent years (e.g., $8.28 in 2034, $8.86 in 2035). These are estimates and not guarantees.
Forecasts indicate bullish sentiment from 2027 onward with rising averages and ROI through the horizon (e.g., 2027 avg $1.45; 2050 avg $18.90; ROI up to 1999.8). These are estimates and should be considered with caution.
Low $0.5175; High $1.57.
CalciMedica, Inc. Community Discussion
0Share your CalciMedica, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.